// App-Quantinova.ai

: Safety and Efficacy of Lenvatinib Plus Nivolumab in Unresectable Hepatocellular Carcinoma: A Retrospective Study in China

Researchers

Presenter

  • X. Huang

Principal Investigators

  • Z. Huang

  • C. Wang

  • X. Yin

  • L. Xu

  • T. Ma

  • Y. Ran

  • X. Bi

  • X. Che

Medical Centers

  • National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Department of Hepatobiliary Surgery, Beijing, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • N/A

Drug/Treatment

  • Lenvatinib

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved